This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
New Zealand shares rose, led higher by a record profit from Skellerup Holdings, as investors focused more on domestic earnings than volatility in global markets. Precinct Properties New Zealand also gained.
CEN AIA FBU FCREY SPKKY NZTCY SPK NZTCF ACKDF FRCEF AUKNY COENY COENF AOTUF SKC AIA FBU CEN SKLUY SKL PFGTF SML
New Zealand shares rose as earnings season continued to deliver mixed results. NZX was among gainers on the day after delivering a special dividend while Heartland Bank fell on its increased bad debt provisioning.
AIA SPKKY NZTCY SPK NZTCF WDT ACKDF AUKNY SKT AOTUF SYKWF AIA SKKTY SKLUY SKL MEZ WFVLF SML
New Zealand shares bounced back from some of yesterday's sell-off as investors are yet to see serious contagion from Turkey's burgeoning financial crisis, led higher by Synlait Milk and A2 Milk Co. Summerset Group Holdings fell after reporting first-half earnings.
AIR FCREY NZTCF ACKDF ANZFY AUKNY AIZ SKT SYKWF SKKTY SNZ SML AIA FBU SPKKY NZTCY SPK FRCEF PGW KWIPF PGWFY AIA FBU ANZLY ANZFF PGWFF MEZ PFGTF
2018-07-27 nzherald.co.nz - 1
The S&P/NZX50 Index rose 63.68 points, or 0.7 per cent, to 8,996.16. Within the index, 25 stocks rose, 17 fell and eight were unchanged. Turnover was $87.5 million.
SKT ZNZ SYKWF THL ZNRGF SKKTY ZEL FTRRF SML
When professional New Zealand golfer Michael Campbell spoke of his deep spiritual feelings for the land it was "like a spear through the chest" for his high-flying international marketer mate and fellow Kiwi Hamish Reid, these days Synlait Milk's environmental guardian.
Outgoing Synlait Milk managing director John Penno says he'd get "bored in about half an hour" lying on a beach but is looking forward to a change of pace after shepherding a single Canterbury dairy farm into a sharemarket darling.
New Zealand shares were mixed in light trading, with Sky Network Television and Stride Property leading gains while A2 Milk Co and Westpac Banking Corp fell.
AIA WBC WEBNF WBK ACKDF AUKNY SKT SYKWF AIA WBC VTHPF SKKTY GTK SML
The Australian sharemarket has recorded only its second advance in the last eight sessions despite a broad retreat of commodity prices overnight.
PILBF RIO DB BLT RIO IAG BEPTF RTPPF GALXF RTNTF MS TWE SML IAUGY PLS TSRYY BHPBF EBOSY EBO BCHEY BPT EBOSF TSRYF GXY IAUGF BHP RIO BBL BHP BHPLF EBO
2018-08-20 - Asif
Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...
2018-08-20 - Asif
Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...
2018-08-20 - Asif
General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...